Predictors for the Use of New Direct Anticoagulants in Atrial Fibrillation and Their One-Year Adherence

Predictores de la elección de nuevos anticoagulantes directos en la fibrilación auricular y su adherencia al año

YANINA B. CASTILLO COSTA1,2, VÍCTOR MAURO1,2, AGOSTINA BARSOTTI1, LUISA HSU1, ADRIÁN CHARASK1,2, ENRIQUE FAIRMAN1,2, FLAVIO DELFINO1, NICOÁL QUINTO2, ALESSIS RAFAELLI1,2, CARLOS BARRERO1,2

ABSTRACT

Background: Men with CHA2DS2-Vasc score \( \geq 1 \) or women with CHA2DS2-Vasc score \( \geq 2 \) and atrial fibrillation/flutter have high indication of antithrombotic treatment.

Objective: The aim of this study was to analyze the prevalence of anticoagulant therapy in this population, to find predictors for the use of new oral anticoagulants and to analyze the one-year adherence to treatment.

Methods: A total of 484 consecutive patients were included in the study. Exclusion criteria were in-hospital mortality (n=12) and CHA2DS2-Vasc score of 0 in both genders and 1 in women (n=67). Finally, 405 patients were analyzed with median age of 76 years, 46% women, 76% hypertensive, 25% diabetic, 10% with previous stroke and 30% with history of atrial fibrillation/flutter.

Results: A rhythm control strategy was used in 66% of cases and 293 patients were anticoagulated at discharge (72%). Among anticoagulated patients, 63.5% received new oral anticoagulants, especially those who were younger (74 vs. 79.5 years, \( p=0.001 \)), with lower history of stroke (5.8% vs.18%, \( p<0.001 \)), lower median CHA 2DS2-Vasc (3 vs.4, \( p<0.01 \)) and HAS-BLED (1 vs. 2, \( p<0.01 \)) scores and with sinus rhythm at discharge (73.8% vs. 54.7%, \( p<0.001 \)). Among 165 patients discharged with new oral anticoagulants and followed up for one year, 55.7% adhered to the indicated new oral anticoagulant, 29.69% had discontinued the anticoagulation treatment and 14.5% had switched to acenocoumarol.

Conclusions: The study shows that only 70 of patients are anticoagulated at discharge. New oral anticoagulants were used in more than half of cases, especially in patients at lower clinical risk. At one-year follow-up, 6 out of every 10 patients with indication of new oral anticoagulants at discharge continue this treatment, 1 switches to acenocoumarol and 3 abandon anticoagulant therapy.

Key words: Atrial fibrillation – Atrial flutter – Anticoagulants - Adherence

RESUMEN

Introducción: Los hombres con CHA2DS2-Vasc \( \geq 1 \) o las mujeres con CHA2DS2-Vasc \( \geq 2 \) y fibrilación/aleteo auricular tienen indicación de tratamiento antitrombótico al alta.

Objetivos: Analizar la prevalencia del uso de anticoagulantes en esta población; hallar predictores del uso de nuevos anticoagulantes orales; y analizar la persistencia al año del tratamiento con nuevos anticoagulantes orales.

Material y métodos: Pacientes consecutivos: 484. Los criterios de exclusión fueron la muerte intrahospitalaria (n: 12) y CHA2DS2-Vasc de 0 en ambos géneros y de 1 en mujeres (67 pacientes). Los pacientes analizados fueron 405. Edad mediana: 76 años, género femenino: 46%, HTA: 76%, diabetes: 25%, accidente cerebrovascular previo: 10%, antecedentes de fibrilación/aleteo auricular: 30%.

Resultados: Estrategia de control de ritmo: 66%. Fueron anticoagulados al alta 293 pacientes (72%). Entre los pacientes anticoagulados, los nuevos anticoagulantes orales fueron los más utilizados: 63,5%, especialmente en los menos añosos (74 versus 79,5 años, \( p=0,001 \)), con menos antecedentes de accidente cerebrovascular (5,8% versus 18%, \( p < 0,001 \)), menor CHA2DS2-Vasc mediana (3 versus 4, \( p < 0,01 \)) y HAS-BLED mediana (1 versus 2, \( p < 0,01 \)) y en más pacientes con ritmo sinusal al momento del alta (73,8% versus 54,7%, \( p < 0,001 \)). De los 165 pacientes externados con nuevos anticoagulantes orales y seguidos al año, el 55,7% mantuvieron el nuevo anticoagulante oral indicado, un 29,69% habían continuado la anticoagulación y el 14,5% rotó a acenocumarol.

Conclusiones: En nuestro trabajo, se anticoagula al alta solo al 70% de los pacientes. Se utilizaron nuevos anticoagulantes orales en más de la mitad de los casos, especialmente en los pacientes de menor riesgo clínico. Al año de seguimiento, cada 10 pacientes medicados al alta con nuevos anticoagulantes orales, 6 persisten con ese tratamiento, 1 rota a acenocumarol y 3 dejan de estar anticoagulados.

Palabras clave: Fibrilación auricular- Aleteo atrial - Anticoagulantes - Adherencia

Abbreviations

| AF/AFl | Atrial fibrillation/atrial flutter |
|--------|-----------------------------------|
| IHD    | In-hospital mortality              |
| NOAC   | New oral anticoagulants            |

REV ARGENT CARDIOL 2019;87:352-356. http://dx.doi.org/10.7775/rac.v87.i6.15198

Received: 05-09-2019 – Accepted: 08-12-2019

Address for reprints: Dra. Yanina Castillo Costa - Av. Directorio 2037 6.° piso - CABA - E-mail: yanu_c@hotmail.com

1 Clínica Santa Isabel. Buenos Aires, Argentina
2 Clínica Bazterrica. Buenos Aires, Argentina
INTRODUCTION
In patients admitted to a coronary care unit due to atrial fibrillation or atrial flutter (AF/AFl) and with a CHA2DS2-Vasc score ≥1 in men or ≥2 in women, it is usually recommended to start antithrombotic therapy at discharge. (1) New oral anticoagulants (NOAC) are effective and safe, have lower risk of intracranial bleeding, are easy to administer and do not require laboratory controls or periodic visits to the hematologist, thus becoming a good treatment option. Current clinical practice guidelines recommend their use over vitamin K antagonists, provided there are no contraindications for their use. (2) However, their use in clinical practice may be restricted due to their high cost or the fear of lack of antidotes.

OBJECTIVES
The aim of this study was to analyze the use of anticoagulation at discharge after hospitalization for AF/AFl, to analyze the clinical characteristics of patients that determine the use of oral antithrombotic therapy and the choice of NOAC, and to evaluate the 1-year adherence in the use of NOAC in our population.

METHODS
Patients admitted to two coronary care units of private institutions due to AF/AFl were prospectively and consecutively included in the study. After calculation of the CHA2DS2-Vasc score, men with CHA2DS2-Vasc ≥1 and women with CHA2DS2-Vasc ≥2 were selected for the analysis.

RESULTS
A total of 484 patients admitted to two coronary care units from January 2015 to December 2018 were included in the study. Fifty-three patients were excluded for presenting CHA2DS2-Vasc score = 0, 14 women for having CHA2DS2-Vasc score = 1 and 12 patients because they died during hospitalization. Finally, 405 patients were analyzed. Median age was 76 years (IQR 25%-75%: 69-83), 46% were women, 76% hypertensive, 25% diabetic, 10% with history of stroke, 3% with history of bleeding and 30% with history of AF/AFl. The median population CHA2DS2-Vasc score was 3 (2-4) and median HAS-BLED score was 2 (1-2). A rhythm control strategy was used in 66% of cases and 68.4% was in sinus rhythm at discharge.

Seventy-two percent of patients received anticoagulant therapy at discharge and 28% had no anticoagulant treatment. Table 1 shows patient characteristics of those receiving anticoagulation compared with those that did not receive it.

Patients who were anticoagulated at discharge were younger, with lower history of AF/AFl (37% vs. 16%, p<0.001), diabetes (27.99 vs. 16.96, p=0.01) and bleeding (0.68 vs. 8.93, p<0.001). Among the variables included in the clinical model to perform the univariate analysis (age >75 years, hypertension, diabetes, history of AF/AFl and history of prior bleeding), only diabetes [OR 2.12 (95% CI 0.95-3.27); p=0.01], history of previous AF/AFl [OR 0.83 (95% CI 1.25-4.41); p=0.0004] and not having history of prior bleeding [OR 20.97 (95% CI 18.64-23.16); p=0.007] were independent predictors of anticoagulation therapy indication at discharge.

Among anticoagulated patients at discharge, 2.3% received enoxaparin, 63.5% NOAC and 34.2% vitamin K antagonists. Table 2 shows patient characteristics according to the type of oral anticoagulation therapy at discharge.

The type of NOAC indicated was apixaban in 78.5% of cases, rivaroxaban in 16% and dabigatran in 5.4%. Patients receiving NOAC therapy were younger (74 vs. 80 years, p<0.001), had lower history of stroke (5.9% vs. 20%, p<0.01), coronary heart disease (9.14% vs. 22%, p=0.022), chronic kidney failure (2.15% vs. 14%, p<0.01), coronary heart disease (9.14% vs. 22%, p=0.022), chronic kidney failure (2.15% vs. 14%, p<0.01), lower mean CHA2DS2-Vasc score (3 vs. 4, p<0.01) and median HAS-BLED score (1 vs. 2, p<0.01) and more patients were in sinus rhythm at discharge (75.28% vs. 53%, p<0.001). In the multivariate analysis, including age >75 years, history of stroke, median CHA2DS2-Vasc and HAS-BLED scores, not having chronic kidney failure and sinus rhythm at discharge, only a lower CHA2DS2-Vasc score (OR 0.72, 95% CI 0.56-0.94), not having kidney failure (OR 0.19, 95% CI 0.10-0.36), p<0.01) and being in sinus rhythm at discharge [OR 0.03 (95% CI 0.95-3.39); p<0.001] preserved their independent predictive capacity.

Median follow-up of patients discharged with NOAC therapy (n=186) was 14 (8-23) months. During this period 8 patients died and 13 were lost to follow-up. Among the 165 followed-up patients, 55.75% remained in treatment at one year, 22.69% had discontinued treatment (median time to discontinuation: 2 months (IQR 25%-75%: 1-4.5 months) and 14.54% had switched to acenocoumarol (median time to
switch: 3.5 months (IQR 25%-75% 2-6 months) since discharge. The treating physician decision was the reason for discontinuation in 87.75% of cases, patient decision in 8.16% and other reasons in 6.12%. In the case of switch from NOAC to acenocoumarol, the reason was due to cost in 41% of cases, treating physician decision in 41% and other reasons in 18%.

DISCUSSION

Atrial fibrillation is the most common sustained arrhythmia and is associated to a fivefold increased risk of major stroke (3) or systemic embolism. Antithrombotic treatment reduces by two-thirds this event (4) and its usefulness is well demonstrated, especially in patients at greater embolic risk. Therefore, national (5) and international (2, 6, 7) guidelines recommend antithrombotic therapy with class Ia indication.

Since 2018, new oral anticoagulants (not dependent on vitamin K) (8) have been added for antithrombotic treatment, and the advantages/disadvantages of their use compared with other therapeutic options poses a clinical challenge. The only available registry of data in our country was performed in 2015, (9) and acenocoumarol was found to be the most recommended anticoagulant agent. In today’s world, there is a trend to increase the use of NOAC because they are easy to administer, do not require hematologist’s controls and patients anticoagulated with vitamin K antagonists are outside the therapeutic range a large part of the time, despite adequately receiving the medication. (10, 11) The disadvantage of NOAC is their elevated cost and, in some cases, the feeling that no antidotes would be available in case of a severe hemorrhage, though the management of these potential complications is currently well established. (12) Moreover, in large clinical trials comparing different NOAC with the usual therapy with vitamin K antagonists, no increased mortality related with bleeding.

Table 1. Patient characteristics according to the use or not of anticoagulation at discharge. Univariate analysis model.

|                         | AC  | No AC | p    |
|-------------------------|-----|-------|------|
| Age (median)            | 76 (68-82) | 78 (69-88) | 0.052 |
| Age>75 years            | 154 (52.56) | 64 (57.4) | 0.23  |
| Female gender           | 134 (45.73) | 53 (47.32) | 0.42  |
| HTN                     | 224 (76.45) | 85 (75.89) | 0.50  |
| DBT                     | 82 (27.99)  | 19 (16.96) | 0.01  |
| Previous stroke         | 31 (10.62)  | 8.93 (10) | 0.38  |
| History of EF <30%      | 13 (4.44)   | 1 (0.89)  | 0.06  |
| History of Cardiovascular disease | 39 (13.31) | 14 (12.5) | 0.48  |
| History of atrial fibrillation | 104 (35.49) | 19 (16.96) | <0.001 |
| Chronic kidney failure  | 18 (6.14)   | 9 (8.04)  | 0.31  |
| CHA2DS2-Vasc score (median) | 3 (2-4)  | 3 (2-4)  | 0.14  |
| Rhythm control          | 197 (67.24) | 71 (63.39) | 0.26  |
| Discharge in SR         | 197 (67.24) | 79 (70.54) | 0.30  |
| HAS-BLED (median)       | 2 (1-2)     | 2 (1-2)   | 0.68  |
| History of bleeding     | 2 (0.68)    | 10 (8.93) | <0.001 |

AC: Anticoagulation. HTN: Hypertension. DBT: Diabetes. EF: Ejection fraction. SR: Sinus rhythm.

Table 2. Patient characteristics according to the type of oral anticoagulant used.

|                         | NOAC  | Vitamin K antagonists | p    |
|-------------------------|-------|-----------------------|------|
| Age (median)            | 74 (66-81) | 80 (72-84) | <0.01 |
| Age>75 years            | 84 (45.16) | 65 (65) | <0.01 |
| Female gender           | 86 (46.24) | 43 (43) | 0.34  |
| HTN                     | 136 (62.39) | 82 (82) | 0.06  |
| DBT                     | 49 (26.34) | 30 (30) | 0.29  |
| Previous stroke         | 11 (5.9) | 20 (20) | <0.01 |
| History of AF           | 63 (33.87) | 40 (40) | 0.18  |
| Chronic kidney disease  | 4 (2.15)      | 14 (14) | 0.0001 |
| History of coronary heart disease | 17 (9.14) | 22 (22) | 0.002 |
| CHA2DS2-Vasc (median)   | 3 (2-4)      | 4 (3-5) | <0.01 |
| Rhythm control          | 141 (75.81) | 53 (53) | <0.001 |
| Discharge in SR         | 140 (75.27) | 53 (53) | <0.001 |
| HAS-BLED (median)       | 1 (1-2)     | 2 (2-3) | <0.01 |
| History of bleeding     | 1 (0.54)    | 1(1)     | 0.59  |

NOAC: New oral anticoagulants. HTN: Hypertension. DBT: Diabetes. AF: Atrial fibrillation. SR: Sinus rhythm.
was observed in patients receiving NOAC. (13-15)

An interesting finding of our study was that, despite the indication, 30% of patients did not receive anticoagulant therapy at hospital discharge. In this sense, this observation is similar to that found in the CONAREC registry and international registries, such as the GARFIELD-AF (16) registry, where 40% of patients did not receive anticoagulant treatment, or the PINNACLE registry where this increased to 60%. (17)

It should be mentioned that in the large international registries mentioned above, including different countries and geographical areas, there is great heterogeneity in the indication of anticoagulation, ranging from 31% to 93% in the GARFIELD-AF registry (16) and 69% to 100% in the ORBIT-AF registry. (18) In addition, as the patients analyzed in the international registries are, in general, ambulatory patients and not recently discharged for arrhythmia, in strict terms, they should not be compared with ours. However, they reflect the reality that not all patients with indication of anticoagulation are receiving treatment and that it is essential to have data disclosing our experience.

In our work, patients with no history of AF received lower prescription of anticoagulant treatment. Nevertheless, current guidelines recommend anticoagulant therapy since the first documented episode, as it is known that patients with recently diagnosed AF are also exposed to considerable risk of stroke, hemorrhage and even, death. Effectively, the GARFIELD-AF registry (19) showed that, even in anticoagulated patients, the one-year incidence of stroke was 1.3%, the rate of major hemorrhage 0.8% and mortality 4.3% (13% of which occurred during the first month). In the same study, during the first 30 days post AF, the rates of stroke and major hemorrhage per 100 person-years was 2.3% (95% CI 1.9-2.8) and 1.5% (95% CI 1.2-1.9), respectively.

The most used anticoagulants after discharge in our population were NOAC. Given the multiple advantages they have, this reality is not surprising and it is even assumed that their use will increase in the next years. (20) In the GLORIA-AF registry (21), NOAC was used in 47.6% of the population and vitamin K antagonists in 32.3% of cases (20.1% did not receive anticoagulation). In the American ORBIT-AF registries, NOAC indication went from 2% in the ORBIT-AF 1 (in 2000) to 71% in the ORBIT-AF 2 (in 2016). Similarly to our work, younger age, lower history of stroke and hemorrhage, preserved kidney function and lower CHA2DS2-Vasc score were predictors of NOAC indication in the ORBIT-AF 2 registry. In their multivariate analysis, factors associated to the use of NOAC were preserved renal function, history of stroke, rhythm control as strategy, treatment by a cardiologist and patient higher educational attainment. (22)

Despite the indisputable benefit of anticoagulation in the prevention of thromboembolism, an elevated percentage of patients have discontinued the medication at one year, ranging between 40% and 60% for vitamin K antagonists in different registries. (23, 24) As NOAC do not require laboratory controls or restrictions in the diet, they could have an advantage in the continuity of therapy, but their cost could also be a barrier for long-term compliance. The evidence of perseverance in the use of NOAC in the real world is lower than with vitamin K antagonists, outside the scenario of clinical trials demonstrating their usefulness, and it is nil in our country. A substudy of the GLORIA-AF registry (44 countries, 5 regions) describes 76.6% continuity with dabigatran use at one year, 69.2% at two years and 63.4% at the end of follow-up. In the XANTUS study with rivaroxaban, treatment continuity at one year was 80%, (25) but in other experiences it was 60.1%, (26), reflecting the heterogeneity of results according to the population analyzed.

Perhaps the greatest strength of our work is to provide current, proper data of two private centers in Buenos Aires, with patients with social work or prepaid healthcare coverage. In our experience, 3 out of 10 patients with anticoagulant indication are not anticoagulated, NOAC are the most used anticoagulants, 6 out of 10 patients continue NOAC medication at one year, 1 switches to acenocoumarol and 3 discontinue anticoagulant therapy. The most frequent cause of NOAC discontinuation in our population was medical indication, but not cost or adverse effects. Similar results were observed in the GLORIA-AF substudy, where the percentages of discontinuation due to cost were also low: in North America 1%, in Europe 3.1%, in Asia 4%, and in Latin America 0%, (27) while discontinuation due to adverse effects occurred in 1 out of 4 patients.

**Limitations**

This information stems from the analysis of a population of patients discharged from the coronary care units of private institutions from the Autonomous City of Buenos Aires, and so the type of anticoagulant indication and the one-year adherence may not be the same for other regions or segments of society. It was not the main purpose of this study to explore the reasons why the treating physician decided to discontinue or not indicate anticoagulation in AF, but due to the medical relevance of this topic and the great clinical impact these decisions entail, we consider that it should be treated in future registries.

Recommendations of anticoagulation for AF have been continuously changing in the last 10 years, and so new bibliography may dynamically influence medical conduct.

**CONCLUSION**

In our setting, 2 out of 3 patients receive anticoagulant treatment at discharge. Most of them are currently using NOAC, especially less elderly patients, without kidney failure and lower embolic and bleeding risk. Six out of 10 patients with NOAC indication at discharge continue with treatment, 1 switches to acenocoumarol and 3 abandon treatment at one year.
Conflicts of interest
None declared.
(See authors’ conflicts of interest forms on the website Supplementary material).

REFERENCES

1. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-72. http://doi.org/e43wq.

2. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74:104-32. http://doi.org/cfrt.

3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-5. http://doi.org/dhwbyv.

4. Antithrombotic Trials Investigators. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86. http://doi.org/crk7m.

5. Consenso de Fibrilación Auricular. Sociedad Argentina de Cardiología. Rev Argent Cardiol 2015;83.

6. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society AHA FA. Circulation. 2014;130:e199-e287.

7. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-62. http://doi.org/b977.

8. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009;361:1139-51. http://doi.org/bcqddq.

9. Roel V, Moukarzel J, Zaidel E, Galli M, Darosa W, Leiva R, Cicero C y cols. Estrategias antitrombóticas en fibrilación auricular. Registro CONAREC XIX. Rev Argent Cardiol 2015;83:210-6. http://doi.org/s8k.

10. Reynolds MW, Fahrbach K, Hauch O, Wygant G, Estok R, Celli C, et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 2004;126:1938-45. http://doi.org/dw6b3.

11. Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009;15:244-52. http://doi.org/bc7z.

12. Consenso para la Prevención y Manejo del Sangrado en Enfermedades Cardiovasculares. Sociedad Argentina de Cardiología. 2017;86(Suplemento 1).

13. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med 2011;365:981-92. http://doi.org/d937vk.

14. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med 2011;365:883-91. http://doi.org/bbcf6w.

15. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51. http://doi.org/bc7z.

16. Camm AJ, Acetta G, Ambrosio G, Atar D, Bassand JP, Berge E, et al; GARFIELD-AF Investigators. Heart 2017;103:307-314. http://doi.org/fpzc4b.

17. Hsu JC, Maddox TM, Kennedy KF, Katz DF, Marzec LN, Lubitz SA, et al. Oral Anticoagulant Therapy Prescription in Patients With Atrial Fibrillation Across the Spectrum of Stroke Risk: Insights From the NCDR PINNACLE Registry. JAMA Cardiol 2016;1:55-62. http://doi.org/cfr3.

18. Steinberg BA, Gao H, Shrader P, Pieper K, Thomas L, Camm AJ, et al; GARFIELD-AF, ORBIT-AF Investigators. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. Am Heart J 2017;194:12-40. http://doi.org/gcrb2.

19. Bassand JP, Virdone S, Goldhaber S, Camm J, Fitzmaurice D, Fox K, et al. Early Risks of Death, Stroke/Systemic Embolism and Major Bleeding in Patients with Newly Diagnosed Atrial Fibrillation: Results from the GARFIELD-AF Registry. http://doi.org/cfr2.

20. Deedwania P, Acharya T. Anticoagulation in atrial fibrillation. Is the Paradigm really shifting? JACC 2017;69:786-8. http://doi.org/cfr4.

21. Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, et al; GLORIA-AF Investigators. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2. J Am Coll Cardiol 2017;69:777-85.

22. Steinberg BA, Shrader P, Thomas L, Ansell J, Fanorow GC, Gersh BJ, et al; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). Am Heart J 2017;189:40-7. http://doi.org/gbmnht.

23. Spivey CA, Qiao Y, Liu X, Mardekian J, Parker RB, Phatak H, et al. Discontinuation/Interuption of Warfarin Therapy in Patients with Nonvalvular Atrial Fibrillation. J Manag Care Spec Pharm 2015;21:596-606. http://doi.org/f9pc4b.

24. Song X, Sander SD, Varker H, Amin A. Patterns and predictors of use of warfarin and other common long-term medications in patients with atrial fibrillation. Am J Cardiovasc Drugs. 2012;12:245-53. http://doi.org/cr95.

25. Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, et al; XANTUS Investigators. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2016;37:1145-53. http://doi.org/f3vc83.

26. Willey V, Franchino-Elder J, Fu AC, Wang C, Sander S, Tan H, et al. Treatment and persistence with oral anticoagulants among newly diagnosed patients with non-valvular atrial fibrillation: a retrospective observational study in a US commercially insured and Medicare Advantage population. BMJ Open 2016;8:e00676. http://doi.org/cr6.

27. Paquette M, Riou França L, Teutsch C, Diener HC, Lu S, Dubner SJ, et al. Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2017;70:1573-83. http://doi.org/gbxxm.